Could CANNABIS SCIENCE INCORPORATED (OTCMKTS:CBIS) See a Reversal After More Sellers Came In?


Investors sentiment increased to 8 in 2017 Q2. Its up 7.00, from 1 in 2017Q1. It increased, as 0 investors sold Cannabis Science Inc shares while 0 reduced holdings. 0 funds opened positions while 0 raised stakes. 359,180 shares or 50.00% less from 718,360 shares in 2017Q1 were reported.
Toth Financial Advisory invested in 11,000 shares or 0% of the stock. Oxbow Ltd accumulated 15,000 shares. 40,000 are owned by North Star Asset. Rothschild Il reported 10,000 shares stake. Frontier Management reported 20,000 shares or 0% of all its holdings. Donaldson Mgmt Llc invested in 0% or 99,780 shares. Neville Rodie & Shaw reported 0% stake. Illinois-based Geneva Advisors Ltd Limited Liability Company has invested 0% in Cannabis Science Inc (OTCMKTS:CBIS). Silvercrest Asset Group Limited Liability Company stated it has 0% of its portfolio in Cannabis Science Inc (OTCMKTS:CBIS). Blair William And Comm Il reported 0% in Cannabis Science Inc (OTCMKTS:CBIS). Massmutual Communications Fsb Adv has invested 0% of its portfolio in Cannabis Science Inc (OTCMKTS:CBIS). Stonebridge Cap Limited Liability reported 0% of its portfolio in Cannabis Science Inc (OTCMKTS:CBIS).

The stock of CANNABIS SCIENCE INCORPORATED (OTCMKTS:CBIS) registered an increase of 177.7% in short interest. CBIS’s total short interest was 635,100 shares in November as published by FINRA. Its up 177.7% from 228,700 shares, reported previously.

The stock increased 0.82% or $0.0003 on November 17, reaching $0.0368. About 7.78M shares traded. Cannabis Science Inc (OTCMKTS:CBIS) has 0.00% since November 19, 2016 and is . It has underperformed by 16.70% the S&P500.

Cannabis Science, Inc. is engaged in medical marijuana research and development. The company has market cap of $92.80 million. The Firm works on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid pharmaceutical products. It currently has negative earnings. The Firm is involved in the creation of cannabis medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

More important recent Cannabis Science Inc (OTCMKTS:CBIS) news were published by: which released: “0.0368” on December 16, 2009, also published article titled: “Emerald Health Therapeutics: Cannabis Science Catalyst”, published: “Cannabis Science Orders First Batch Inhalation Medication and Adds CBIS MDI …” on August 11, 2016. More interesting news about Cannabis Science Inc (OTCMKTS:CBIS) was released by: and their article: “Cannabis Science Set to Launch its Online Community for Doctors, Patients …” with publication date: November 16, 2017.